Video

Experts Highlight Anticipated Research to Be Revealed at ESMO 2019

Author(s):

OncLive Staff
Conference|ESMO Congress

OncLive interviewed experts at the State of the Science Summits™ in September 2019 on anticipated research to be presented at the 2019 ESMO Congress.

OncLive interviewed experts at the State of the Science Summits™ in September 2019 on anticipated research to be presented at the 2019 ESMO Congress.

Related Videos
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Arvind N. Dasari, MD, MS
Charles E. Geyer, Jr., MD
Sattva S. Neelapu, MD
Related Content
Meredith McKean, MD
October 17th 2024

Experts Highlight Noteworthy Research From the 2024 ESMO Congress

Wolfgang Janni, MD, PhD
October 2nd 2024

Trastuzumab/Pertuzumab May Be an Effective Chemo-Free Regimen in HR+/HER2+ Breast Cancer

Targeted Treatment in Pretreated Metastatic Solid Tumors | Image Credit: © catalin - stock.adobe.com
October 1st 2024

Targeted Treatment Provides ORR and PFS Benefit in Pretreated Metastatic Solid Tumors

RCC: stock.adobe.com
October 1st 2024

Fecal Microbiota Transplantation Boosts Response to Pembrolizumab Plus Axitinib in mRCC

John Andrew Livingston, MD, MS
September 25th 2024

Experts Share Intriguing Early-Phase Sarcoma Studies From the 2024 ESMO Congress

Andrea B. Apolo, MD
September 25th 2024

Adjuvant Pembrolizumab Prolongs DFS Regardless of PD-L1 or Nodal Status in High-Risk MIBC